Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amy J Johnson

Showing results (51-60 of 121) with videos related to

Pageof 13
Sort By:
Cancer Medicine|March 17, 2017
The regulation of tumor-suppressive microRNA, miR-126, in chronic lymphocytic leukemiaDaphne Guinn, Amy Lehman, Catherine Fabian, et al.
Blood|May 19, 2017
NF-κB p50 (<i>nfkb1</i>) contributes to pathogenesis in the Eμ-TCL1 mouse model of chronic lymphocytic leukemiaTimothy L Chen, Minh Tran, Aparna Lakshmanan, et al.
British Journal of Haematology|October 31, 2025
Enitociclib (VIP152), venetoclax and prednisone in relapsed or refractory aggressive non-Hodgkin lymphomaMax J Gordon, Rahul Lakhotia, Stefania Pittaluga, et al.
Blood|March 8, 2011
The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemiaSarah E M Herman, Rosa Lapalombella, Amber L Gordon, et al.
Leukemia & Lymphoma|March 6, 2009
Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphomaKristie A Blum, Mehdi Hamadani, Gary S Phillips, et al.
Blood|March 22, 2014
Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicityHolbrook E Kohrt, Idit Sagiv-Barfi, Sarwish Rafiq, et al.
The Journal of Clinical Investigation|November 21, 2018
PI3K p110δ inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppressionShuai Dong, Bonnie K Harrington, Eileen Y Hu, et al.
Blood|March 23, 2011
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765Sarah E M Herman, Amber L Gordon, Erin Hertlein, et al.
Blood|September 7, 2013
Lymphocyte cytosolic protein 1 is a chronic lymphocytic leukemia membrane-associated antigen critical to niche homingJason A Dubovsky, Danielle L Chappell, Bonnie K Harrington, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 29, 2014
Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortiumDanelle F James, Lillian Werner, Jennifer R Brown, et al.
Pageof 13

Showing results (51-60 of 121) with videos related to

Sort By:
Pageof 13
Cancer Medicine|March 17, 2017
The regulation of tumor-suppressive microRNA, miR-126, in chronic lymphocytic leukemiaDaphne Guinn, Amy Lehman, Catherine Fabian, et al.
Blood|May 19, 2017
NF-κB p50 (<i>nfkb1</i>) contributes to pathogenesis in the Eμ-TCL1 mouse model of chronic lymphocytic leukemiaTimothy L Chen, Minh Tran, Aparna Lakshmanan, et al.
British Journal of Haematology|October 31, 2025
Enitociclib (VIP152), venetoclax and prednisone in relapsed or refractory aggressive non-Hodgkin lymphomaMax J Gordon, Rahul Lakhotia, Stefania Pittaluga, et al.
Blood|March 8, 2011
The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemiaSarah E M Herman, Rosa Lapalombella, Amber L Gordon, et al.
Leukemia & Lymphoma|March 6, 2009
Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphomaKristie A Blum, Mehdi Hamadani, Gary S Phillips, et al.
Blood|March 22, 2014
Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicityHolbrook E Kohrt, Idit Sagiv-Barfi, Sarwish Rafiq, et al.
The Journal of Clinical Investigation|November 21, 2018
PI3K p110δ inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppressionShuai Dong, Bonnie K Harrington, Eileen Y Hu, et al.
Blood|March 23, 2011
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765Sarah E M Herman, Amber L Gordon, Erin Hertlein, et al.
Blood|September 7, 2013
Lymphocyte cytosolic protein 1 is a chronic lymphocytic leukemia membrane-associated antigen critical to niche homingJason A Dubovsky, Danielle L Chappell, Bonnie K Harrington, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 29, 2014
Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortiumDanelle F James, Lillian Werner, Jennifer R Brown, et al.
Pageof 13